PZRX - PhaseRx, Inc.

. Currency in USD
-
-
Stock chart is not supported by your current browser
Previous CloseN/A
OpenN/A
BidN/A x N/A
AskN/A x N/A
Day's RangeN/A - N/A
52 Week Rangeundefined - undefined
VolumeN/A
Avg. VolumeN/A
Market CapN/A
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • PR Newswire9 months ago

    PhaseRx Receives Decision from the Nasdaq Hearings Panel for Continued Listing of Shares

    SEATTLE, Dec. 13, 2017 /PRNewswire/ -- PhaseRx, Inc. (PZRX), a biopharmaceutical company developing mRNA treatments for life-threatening inherited liver diseases in children, today announced it received a decision from the Nasdaq Hearings Panel (the "Panel") granting PhaseRx's request for continued listing on The Nasdaq Capital Market until January 31, 2018. On or before January 31, 2018, Company shall inform the Panel that the Section 363 sale is complete, at which time the shares will be delisted from the Nasdaq Stock Market. Should events occur that call into question the ability of the Company to complete the sale through the bankruptcy process on a timeline consistent with its representations at the hearing, it should so inform the Panel immediately.

  • PhaseRx Inc (PZRX) Investors Run for the Hills Following Bankruptcy News
    SmarterAnalyst9 months ago

    PhaseRx Inc (PZRX) Investors Run for the Hills Following Bankruptcy News

    Monday turned out to be a nightmare for PhaseRx Inc (NASDAQ:PZRX) investors after the biopharmaceutical firm announced that it has filed for Chapter 11 bankruptcy protection. PhaseRx expects to continue to manage and operate its business under the jurisdiction of the Bankruptcy Court and in accordance with the applicable provisions of the Bankruptcy Code and the orders of the Bankruptcy Court. Contemporaneous with the filing of the Chapter 11 petition, the company is working with Cowen and Company to review financial and strategic alternatives with the goal of maximizing stockholder value.

  • PR Newswire9 months ago

    PhaseRx Commences Voluntary Chapter 11 Bankruptcy Protection Proceeding

    SEATTLE, Dec. 11, 2017 /PRNewswire/ -- PhaseRx, Inc. (PZRX), a biopharmaceutical company developing mRNA treatments for life-threatening inherited liver diseases in children, today announced that it has elected to file a voluntary petition under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware. PhaseRx intends to continue to manage and operate its business under the jurisdiction of the Bankruptcy Court and in accordance with the applicable provisions of the Bankruptcy Code and the orders of the Bankruptcy Court. The company is working with Cowen and Company to review financial and strategic alternatives with the goal of maximizing stockholder value.

  • SmarterAnalyst10 months ago

    PhaseRx Inc (PZRX) Stock Rallies on Investor Optimism Over Orphan Drug Designation in the European Union

    Shares of PhaseRx Inc (NASDAQ:PZRX) skyrocket over 70% today, after the drug maker announced that the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) issued a positive opinion on the Orphan Medicinal Product Application for PRX-ASL, for the treatment of argininosuccinate lyase deficiency (ASLD). To be eligible for orphan medicinal product designation, the Company had to establish medically plausible evidence that PRX-ASL will provide a significant benefit over existing approved therapies in the European Union for the treatment of ASLD.

  • PhaseRx Receives Positive Opinion for Orphan Drug Designation for PRX-ASL from European Medicines Agency
    PR Newswire10 months ago

    PhaseRx Receives Positive Opinion for Orphan Drug Designation for PRX-ASL from European Medicines Agency

    SEATTLE, Nov. 28, 2017 /PRNewswire/ -- PhaseRx, Inc. (PZRX), a biopharmaceutical company developing mRNA treatments for life-threatening inherited liver diseases in children, today announced that the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP) has issued a positive opinion recommending orphan medicinal product (orphan drug) designation for PRX-ASL, for the treatment of argininosuccinate lyase deficiency (ASLD), PhaseRx's second drug candidate to treat a urea cycle disorder.

  • PhaseRx Reports Third Quarter 2017 Financial Results and Provides Corporate Update
    PR Newswire10 months ago

    PhaseRx Reports Third Quarter 2017 Financial Results and Provides Corporate Update

    SEATTLE , Nov. 9, 2017 /PRNewswire/ -- PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company developing mRNA treatments for life-threatening inherited liver diseases in children, today reported financial ...

  • Does PhaseRx Inc’s (PZRX) Debt Level Pose A Serious Problem?
    Simply Wall St.11 months ago

    Does PhaseRx Inc’s (PZRX) Debt Level Pose A Serious Problem?

    Investors are always looking for growth in small-cap stocks like PhaseRx Inc (NASDAQ:PZRX), with a market cap of USD $8.07M. However, an important fact which most ignore is: how financiallyRead More...

  • PhaseRx Receives Delisting Notice from Nasdaq and Evaluates Listing Options
    PR Newswire11 months ago

    PhaseRx Receives Delisting Notice from Nasdaq and Evaluates Listing Options

    SEATTLE, Oct. 26, 2017 /PRNewswire/ -- PhaseRx, Inc. (PZRX), a biopharmaceutical company developing mRNA treatments for life-threatening inherited liver diseases in children, today announced receipt of a delisting notice from Nasdaq, which informed the company that, absent an appeal, trading in PhaseRx's common stock will be suspended from Nasdaq at the opening of business on November 1, 2017. PhaseRx will appeal the decision to a Nasdaq Hearing Panel, which will stay the suspension of their securities, pending the panel's decision subsequent to the hearing. PhaseRx received notification from the Listing Qualifications Department of the Nasdaq Stock Market on August 22, 2017, indicating that the company no longer complied with the minimum stockholders' equity requirement under Nasdaq Listing Rule 5550(b)(1) for continued listing on the Nasdaq Capital Market.

  • ACCESSWIRE11 months ago

    Featured Company News - PhaseRx Announces Cutback in Workforce; Considers Corporate Restructuring

    LONDON, UK / ACCESSWIRE / October 17, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for PhaseRx, Inc. (NASDAQ: PZRX ), following which we have published ...

  • PhaseRx Announces Corporate Restructuring and Review of Strategic Alternatives
    PR Newswire11 months ago

    PhaseRx Announces Corporate Restructuring and Review of Strategic Alternatives

    SEATTLE, Oct. 13, 2017 /PRNewswire/ -- PhaseRx, Inc. (PZRX), a biopharmaceutical company developing mRNA treatments for life-threatening inherited liver diseases in children, today announced that its board of directors has made a determination to conduct a restructuring of operations to reduce short term operating costs and delay the development of its lead product candidate PRX-OTC. The company has not set a timetable for this process. No decision has been made as to whether the company will engage in a transaction or transactions and there can be no assurance that the review of strategic alternatives will result in a transaction, or the terms or timing of any potential transaction that may take place.